GET DAILY SIGNALSAmneal Pharmaceuticals (AMRX) Delivers Q3 Beat and Raises 2026 Guidance for the Third Time
Key Takeaways
- Amneal reported third quarter 2026 net revenue of $862.7 million, up 10% year over year and above the roughly $812–$826 million consensus estimate.
- Adjusted diluted earnings per share (EPS) came in at $0.26, up 53% from $0.17 a year ago and ahead of the approximately $0.23 consensus.
- Adjusted EBITDA rose 30% to $207 million, driven by higher gross profit and lower operating expenses.
- On a GAAP basis, the company posted a net loss of about $22 million, or a $0.06 diluted loss per share, reflecting one-time acquisition and integration costs tied to the Kashiv deal.
- Management raised full-year 2026 guidance for a third consecutive time, lifting revenue, adjusted EBITDA, and adjusted EPS ranges.
- You can find more information about this ticker's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- Explore Trending AI Robots to see AI-driven trading strategies across the market.
Earnings Context and Why It Matters
Amneal Pharmaceuticals has shown a consistent pattern of beating expectations and lifting its outlook throughout 2026, which makes each quarterly update an important checkpoint for investors following the company’s progress. The third quarter was the first full period reflecting integration of Kashiv Biosciences, a strategic acquisition that broadens biosimilar capacity and pipeline. With growth accelerating in both the Affordable Medicines and Specialty segments, the report served as a test of whether the company could maintain double-digit revenue growth while handling acquisition-related costs. For shareholders, the numbers provided clearer insight into margin trends, segment performance, and the reliability of management’s increasingly positive full-year guidance.
Reported Results
For the third quarter ended September 30, 2026, Amneal posted net revenue of $862.7 million, a 10% increase from $784.5 million in the prior-year period and ahead of consensus estimates ranging from roughly $812 million to $826 million. Gross profit rose to $334.1 million from $274.0 million, improving gross margin to 38.7% from 34.9% a year earlier. Operating income nearly doubled to $95.4 million from $70.3 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On an adjusted basis, diluted EPS increased 53% to $0.26 from $0.17, beating the approximately $0.23 consensus. Adjusted EBITDA grew 30% to $207 million. On a GAAP basis, however, the company recorded a net loss of about $22 million, or a $0.06 diluted loss per share, compared with net income of roughly $2 million a year ago. The change was largely due to $22.3 million in acquisition and integration costs related to Kashiv, along with a higher tax provision.
Segment performance was generally solid. Affordable Medicines revenue rose 19% to $547 million, supported by biosimilars, women’s health patches, and new launches, while Specialty revenue climbed 20% to about $150 million, led by branded products including CREXONT, the BREKIYA autoinjector, and UNITHROID. AvKARE revenue fell 17% as expected, reflecting a non-recurring cardiovascular product launch in the prior year.
Management also raised full-year 2026 guidance to net revenue of $3.15–$3.25 billion, adjusted EBITDA of $800–$815 million, and adjusted diluted EPS of $1.04–$1.08.
Market Reaction and Investor Sentiment
Despite the beat on adjusted EPS and revenue plus the third straight guidance increase, Amneal shares traded lower after the report, slipping roughly 5% from a close near $20.44 ahead of the announcement. The reaction indicates investors focused more on the GAAP swing to a loss, the acquisition-driven costs, and fourth-quarter guidance that pointed to sequential moderation in revenue and adjusted EBITDA. The stock had already rallied strongly into the print—up about 80% over the prior twelve months—leaving room for profit-taking. Sentiment stays constructive on the underlying growth story, yet the post-earnings move underscores sensitivity to leverage, integration expenses, and cash-flow considerations.
Forward Outlook and Key Factors to Monitor
Looking ahead, the key question is whether Amneal can translate its revenue momentum into sustainable profitability while absorbing the Kashiv acquisition. The updated full-year guidance implies fourth-quarter revenue near $820 million and adjusted EBITDA around $190 million—both below third-quarter levels—so investors will watch whether the company can exceed those embedded assumptions, especially with a lanreotide launch approaching.
Integration of Kashiv remains the most critical operational factor. The deal expands biosimilar drug-substance capacity and adds a meaningful pipeline, but it also brings acquisition and integration costs plus higher goodwill and intangible assets on the balance sheet. Progress on cost synergies, biosimilar approvals, and commercial launches will determine how quickly the transaction becomes accretive.
Margin trends across segments also warrant attention. Affordable Medicines and Specialty delivered double-digit growth, but AvKARE faces a tough comparison. Investors should track gross margin durability, new product launch timing, and any residual effects from the earlier flood at the company’s India site. Leverage and cash-flow trends will stay in focus as management targets net leverage below 3x by 2028.
AI Tools in My Research Process
I often turn to Tickeron’s AI Screener when evaluating companies like this one. It lets me quickly filter for comparable names, review technical patterns, and cross-check fundamentals against peers. The tool has become a regular part of how I prepare for earnings season and monitor post-report moves.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AMRX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for AMRX turned positive on October 23, 2026. Looking at past instances where AMRX's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on AMRX as a result. In 66 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +1.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRX advanced for three days, in 243 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for AMRX moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In 33 of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
AMRX broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. AMRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AMRX's P/B Ratio (215.576) is very high in comparison to the industry average of (8.029). P/E Ratio (40.880) is within average values for comparable stocks, (-0.853). Projected Growth (PEG Ratio) (1.947) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (1.899) is also within normal values, averaging (178.797).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products
Industry PharmaceuticalsGeneric
Advertisement